SAGE: SAGE Therapeutics, Inc.
About
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Current Value
$4.751 Year Return
Current Value
$4.751 Year Return
Key Details
Market Cap
$300.36M
P/E Ratio
-0.88
1Y Stock Return
-74.61%
1Y Revenue Growth
837.52%
Dividend Yield
0.00%
Price to Book
0.5
Strategies that include SAGE
Stock's related to SAGE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 47.33% | $2.09B | -9.52% | 0.00% |
| QRVO | 46.52% | $6.27B | -28.83% | 0.00% |
| CRSP | 45.34% | $4.01B | -30.49% | 0.00% |
| MBUU | 45.26% | $795.51M | -13.00% | 0.00% |
| VIR | 42.56% | $954.40M | -26.51% | 0.00% |
| PGEN | 41.62% | $228.91M | -28.00% | 0.00% |
| GIC | 41.50% | $1.04B | -25.63% | 3.67% |
| OPCH | 41.40% | $3.71B | -27.12% | 0.00% |
| COTY | 40.79% | $6.17B | -34.71% | 0.00% |
| AVNS | 39.97% | $818.03M | -16.00% | 0.00% |
| GPRO | 39.92% | $179.52M | -67.23% | 0.00% |
| HRMY | 39.70% | $1.85B | +18.24% | 0.00% |
| MGTX | 39.11% | $467.36M | +9.12% | 0.00% |
| HCSG | 39.08% | $832.59M | +14.29% | 0.00% |
| PLRX | 38.78% | $778.32M | -9.55% | 0.00% |
| DDD | 38.40% | $402.06M | -35.13% | 0.00% |
| ALLO | 37.62% | $444.50M | -24.82% | 0.00% |
| BIGC | 37.59% | $473.42M | -31.75% | 0.00% |
| ARWR | 37.49% | $2.31B | -34.44% | 0.00% |
| RYTM | 37.45% | $3.69B | +79.50% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LLY | -0.03% | $692.74B | +23.14% | 0.71% |
| CYD | -0.12% | $364.46M | -2.94% | 4.26% |
| VHC | 0.16% | $19.06M | -38.36% | 0.00% |
| UNM | -0.18% | $13.16B | +69.20% | 2.16% |
| PG | 0.21% | $402.15B | +14.14% | 2.33% |
| MANH | 0.24% | $16.54B | +21.25% | 0.00% |
| UIS | 0.30% | $511.20M | +51.33% | 0.00% |
| VNOM | 0.31% | $5.48B | +79.62% | 3.35% |
| GHI | -0.32% | $272.26M | -27.60% | 12.75% |
| CANG | 0.34% | $253.50M | +212.50% | 0.00% |
| VSTA | 0.54% | $204.94M | -39.33% | 0.00% |
| AFL | -0.56% | $61.74B | +35.69% | 1.35% |
| MSDL | -0.81% | $1.83B | +0.66% | 7.26% |
| VRSK | 0.89% | $39.77B | +17.45% | 0.53% |
| KSPI | -1.02% | $20.86B | +18.06% | 3.37% |
| NOC | 1.02% | $71.54B | +4.23% | 1.60% |
| FATBB | 1.06% | $81.94M | -12.91% | 11.69% |
| EDU | 1.26% | $9.06B | -22.20% | 0.00% |
| QTTB | 1.27% | $354.34M | +188.64% | 0.00% |
| LITB | 1.46% | $35.48M | -75.45% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GRMN | -17.57% | $39.82B | +73.79% | 1.43% |
| OMCL | -14.39% | $1.96B | +30.61% | 0.00% |
| TCTM | -12.13% | $8.10M | -42.99% | 0.00% |
| PULM | -9.43% | $19.83M | +202.98% | 0.00% |
| HUSA | -7.68% | $16.69M | -11.56% | 0.00% |
| STG | -7.59% | $35.67M | +7.92% | 0.00% |
| LMT | -7.17% | $126.40B | +18.99% | 2.36% |
| K | -7.10% | $27.77B | +52.50% | 2.79% |
| HIHO | -6.26% | $8.63M | 0.00% | 6.12% |
| BTCT | -5.99% | $42.61M | +353.33% | 0.00% |
| MCK | -5.39% | $78.15B | +35.51% | 0.42% |
| LPLA | -5.35% | $23.55B | +38.13% | 0.38% |
| TAC | -5.31% | $3.09B | +31.01% | 1.68% |
| CHD | -5.15% | $27.18B | +19.50% | 1.03% |
| MNR | -4.88% | $1.66B | -10.71% | 15.90% |
| PRPO | -4.71% | $9.10M | -13.65% | 0.00% |
| CME | -4.24% | $82.76B | +9.21% | 1.98% |
| SUN | -4.05% | $7.32B | +1.51% | 6.47% |
| MNOV | -4.02% | $93.19M | +2.15% | 0.00% |
| LPTH | -3.88% | $62.27M | +33.05% | 0.00% |
ETF's related to SAGE
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SMMV | 49.36% | $321.07M | 0.2% |
| DFAT | 49.26% | $11.16B | 0.28% |
| VIOV | 49.22% | $1.44B | 0.15% |
| EFAA | 48.01% | $117.38M | 0% |
| XBI | 47.42% | $6.58B | 0.35% |
| IWC | 47.02% | $933.99M | 0.6% |
| QQA | 46.99% | $135.01M | 0% |
| IWO | 46.42% | $12.56B | 0.24% |
| IBB | 46.41% | $6.66B | 0.45% |
| SPSM | 46.09% | $12.72B | 0.03% |
| EZM | 46.06% | $823.84M | 0.38% |
| FYX | 45.85% | $959.00M | 0.6% |
| JMEE | 45.83% | $1.51B | 0.24% |
| SMLF | 45.78% | $1.44B | 0.15% |
| VBK | 45.56% | $19.31B | 0.07% |
| SPHB | 45.09% | $365.01M | 0.25% |
| VTWO | 44.69% | $12.38B | 0.1% |
| IJT | 44.67% | $6.64B | 0.18% |
| IWM | 44.64% | $75.73B | 0.19% |
| IJR | 44.62% | $90.05B | 0.06% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BILZ | -0.32% | $563.02M | 0.14% |
| JUCY | -0.40% | $324.29M | 0.6% |
| CSHI | -0.85% | $482.85M | 0.38% |
| BSCO | 1.02% | $2.35B | 0.1% |
| MINT | -1.14% | $11.62B | 0.35% |
| JBBB | -1.51% | $1.26B | 0.49% |
| DBA | 1.58% | $755.88M | 0.93% |
| XBIL | -1.80% | $637.70M | 0.15% |
| SGOV | 1.95% | $27.53B | 0.09% |
| BOXX | 2.14% | $4.43B | 0.1949% |
| FLRN | 2.33% | $2.33B | 0.15% |
| UNG | 3.46% | $908.80M | 1.06% |
| SOYB | 4.57% | $27.32M | 0.22% |
| CCOR | 4.63% | $109.04M | 1.18% |
| CORN | -4.72% | $61.12M | 0.2% |
| IBHD | 4.76% | $327.80M | 0.35% |
| COMT | 5.05% | $829.06M | 0.48% |
| MUST | 5.16% | $410.00M | 0.23% |
| HDRO | 5.23% | $164.26M | 0.3% |
| GSG | 5.24% | $914.42M | 0.75% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -36.30% | $388.04M | 1.43% |
| VIXY | -25.52% | $195.31M | 0.85% |
| USDU | -14.08% | $201.97M | 0.5% |
| UUP | -13.48% | $309.25M | 0.77% |
| TAIL | -13.32% | $67.98M | 0.59% |
| EQLS | -8.56% | $76.08M | 1% |
| TBIL | -8.17% | $4.38B | 0.15% |
| DBO | -7.72% | $217.57M | 0.77% |
| KCCA | -7.36% | $220.51M | 0.87% |
| DBE | -7.28% | $50.13M | 0.77% |
| CTA | -7.28% | $350.27M | 0.78% |
| WEAT | -7.01% | $120.27M | 0.28% |
| KMLM | -6.46% | $353.87M | 0.9% |
| CLOI | -6.23% | $715.40M | 0.4% |
| KRBN | -6.10% | $242.47M | 0.85% |
| AGZD | -5.62% | $142.76M | 0.23% |
| CORN | -4.72% | $61.12M | 0.2% |
| XBIL | -1.80% | $637.70M | 0.15% |
| JBBB | -1.51% | $1.26B | 0.49% |
| MINT | -1.14% | $11.62B | 0.35% |
News
Yahoo
On Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD), an inherited brain disorder that causes nerve cells in the brain to break down and die. In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (S
Yahoo
Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.
Yahoo
CAMBRIDGE, Mass., November 20, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not
Finnhub
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the Treatment of Cognitive Impairment Associated with Huntington's Disease ...
SeekingAlpha
Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling.
Yahoo
Piper Sandler lowered the firm’s price target on Sage Therapeutics (SAGE) to $26 from $52 to reflect the company’s re-priotization on Zurzuvae, while keeping an Overweight rating on the shares. The firm notes Sage announced another strong quarter for Zurzuvae’s launch with $11M in collaboration revenue from about 2K scripts shipped and delivered in Q3. With Phase 2 DIMENSION topline guided for Q4 2024, the bogey is a clinically meaningful separation in SDMT between dalzanemdor-treated patients v
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.